Perimeter Announces Grant and Cancellation of Stock Options
MWN-AI** Summary
Perimeter Medical Imaging AI, Inc. (TSXV: PINK) recently announced a strategic move involving the grant and cancellation of stock options affecting key employees and consultants. The company intends to cancel up to 2,175,619 previously issued stock options, known as the "Original Options," which were granted to 27 employees and consultants. These Original Options, which had exercise prices between C$0.38 and C$2.85, will be replaced with an equal number of new stock options, referred to as the "Replacement Options," that will have a lower exercise price of C$0.30 per common share.
The Replacement Options will vest over varying timelines: approximately 1,849,000 options will vest monthly over four years, 234,125 options will vest monthly over three years, and 92,504 options will vest monthly over one year, all commencing January 1, 2026. Notably, these adjustments are classified as a re-pricing under the policies of the TSX Venture Exchange, and the changes await approval from the Exchange. Importantly, no directors or officers of the company will participate in this stock option cancellation or issuance.
Perimeter is a medical technology firm focused on revolutionary advancements in cancer surgery through its imaging products, including the Perimeter S-Series OCT system. This FDA-cleared technology provides real-time, high-resolution tissue visualization. Recently, Perimeter was awarded a grant of up to US$7.4 million from the Cancer Prevention and Research Institute of Texas to support its innovative initiatives.
Overall, this announcement reflects Perimeter's proactive approach in managing its employee incentive programs while ensuring alignment with its strategic goals in the medical technology space.
MWN-AI** Analysis
Perimeter Medical Imaging AI, Inc. recently announced a strategic move to cancel existing stock options and issue new ones to employees and consultants. This action, involving the re-pricing of 2,175,619 stock options from an exercise price of C$0.38 to C$2.85 down to C$0.30, represents a crucial step for the company as it aims to retain and incentivize key personnel amid a challenging market environment.
For investors, this decision indicates management's commitment to long-term growth and stability. By replacing older, more expensive options with cheaper alternatives, Perimeter is likely trying to enhance employee motivation and align their interests more closely with those of shareholders. It may also alleviate concerns surrounding employee retention, particularly as the company navigates its strategic objectives within the competitive medical technology landscape.
Moreover, the announcement comes in light of Perimeter's advancements in cancer imaging technologies, including its FDA-cleared S-Series OCT system, which provides real-time tissue visualization. This positions Perimeter as a potential leader in its field, especially given the growing demand for innovative surgical solutions. However, investors should consider the volatility typically associated with biotech and medical tech stocks, particularly around regulatory approvals and clinical trial outcomes.
As the company's actions are subject to approval from the TSX Venture Exchange, it’s crucial for shareholders to monitor any updates regarding the approval process and overall market conditions affecting Perimeter. Moreover, with potential upside in its technology and health sector growth trends, investors might find this an opportune entry point, accompanied by a watchful eye on future developments in both the company's operational landscape and broader market dynamics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
TORONTO and DALLAS, Feb. 17, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announces its intention to enter into cancellation agreements with certain employees and consultants of the Company, pursuant to which it will cancel and grant stock options to such employees and consultants.
The Company intends to enter into such cancellation agreements, pursuant to which it will cancel up to 2,175,619 previously issued stock options (the "Original Options"), exercisable at prices ranging from C$0.38 to C$2.85, granted to 27 employees and consultants of the Company. In replacement for such cancelled Original Options, the Company intends to grant up to 2,175,619 stock options (the "Replacement Options") to such employees and consultants entitling them to acquire up to 2,175,619 common shares at a price of C$0.30 per common share. The Replacement Options are expected to vest as follows: (i) 1,848,990 Replacement Options vest at 1/48 per month, beginning January 1, 2026; (ii) 234,125 Replacement Options vest at 1/36 per month, beginning January 1, 2026; and (iii) the remaining 92,504 Replacement Options vest 1/12 per month, beginning January 1, 2026. The Replacement Options will continue to have the same expiry date as the Original Options which they are replacing.
No directors or officers of the Company will enter into cancellation agreements, have Original Options cancelled or receive Replacement Options.
The cancellation of the Original Options and issuance of the Replacement Options is considered a re-pricing under the policies of the TSX Venture Exchange and remains subject to the approval of the TSX Venture Exchange.
About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that was recently evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The Company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.
S-Series OCT Intended Use and Unapproved Uses
The S-Series OCT is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization with image review manipulation software for identifying and annotating regions of interest. Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit www.perimetermed.com/disclosures.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Annual Information Form for the year ended December 31, 2024, which is available on Perimeter's SEDAR+ profile at https://www.sedarplus.ca, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.
Contacts
Stephen Kilmer
Investor Relations
Direct: 647-872-4849
Email: skilmer@perimetermed.com
Adrian Mendes
Chief Executive Officer
Toll-free: 888-988-7465 (PINK)
Email: investors@perimetermed.com
SOURCE Perimeter Medical Imaging AI Inc.
FAQ**
How does the cancellation and grant of stock options by Perimeter Medical Imaging AI Inc. (PYNKF) reflect the company's overall strategy for employee retention and motivation in the competitive medical technology sector?
What are the expected financial implications for Perimeter Medical Imaging AI Inc. (PYNKF) stemming from the re-pricing of stock options, particularly in light of the recently announced grant from the Cancer Prevention and Research Institute of Texas?
With the Replacement Options set to vest over different timelines, how does Perimeter Medical Imaging AI Inc. (PYNKF) plan to ensure that employees stay engaged and focused on the company's long-term objectives during this vesting period?
Given that no directors or officers of Perimeter Medical Imaging AI Inc. (PYNKF) will participate in the cancellation agreements, how does this decision align with the company's governance policies and overall vision for equity management?
**MWN-AI FAQ is based on asking OpenAI questions about Perimeter Medical Imaging AI Inc (OTC: PYNKF).
NASDAQ: PYNKF
PYNKF Trading
-11.34% G/L:
$0.3308 Last:
33,900 Volume:
$0.3594 Open:
